Prognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study
Authors:
Open Access
- 24 September 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1936498
Abstract
Objective: Gastric cancer (GC) remains a leading cause of cancer-related mortality globally. While molecular targeted therapies against HER2 and PD-L1 have advanced, the role of receptor tyrosine kinase (RTK) co-activation, specifically between c-MET and EGFR, remains elusive in GC. This study aimed to investigate the correlation between c-MET and EGFR overexpression and clinicopathological features and prognosis in patients with gastric cancer, and to reveal prognostic significance of co-expression of c-MET and EGFR in gastric adenocarcinoma. Methods: The clinicopathological data of 214 Chinese patients with GC were retrospectively analyzed, and the expression level of c-MET and EGFR were detected by immunohistochemistry. χ 2 test was used to investigate associations with clinicopathological features. Kaplan-Meier survival curve and Cox proportional hazards models were employed to analyze the relationship between c-MET, EGFR and co-expression and patient prognosis. Results: The positive expression rates for c-MET and EGFR were 21.96% (47/214) and 68.22% (146/214), respectively. c-MET overexpression was significantly served as an independent predictor of poor OS ( P=0.023 ). Conversely, EGFR expression alone showed no significant prognostic value. Notably, 18.22% (39/214) of cases exhibited co-expression of c-MET and EGFR. Patients with isolated EGFR expression exhibited the most favorable prognosis, while the isolated c-MET expression group had the worst clinical survival. Moreover, patients with c-MET and EGFR co-expression achieved better survival than those with isolated c-MET expression ( P = 0.007 ). Conclusion: c-MET overexpression is a robust prognostic indicator of adverse outcomes in GC. The frequent co-expression of c-MET and EGFR suggests a potential mechanism of RTK cross-talk, warranting further investigation into dual-targeted therapeutic strategies.Keywords
Funding Information
- Youth Science Fund Project (81502042)
This publication has 28 references indexed in Scilit:
- Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial resultsCell Reports Medicine, 2023
- Savolitinib: First ApprovalDrugs, 2021
- Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategyGastric Cancer, 2015
- c-Met targeting in advanced gastric cancer: An open challengeCancer Letters, 2015
- HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapyInternational Journal of Cancer, 2014
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinomaGastric Cancer, 2014
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerInvestigational New Drugs, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010